Denali Partner Sanofi Reports the Patient Dosing in P-II (HIMALAYA) Study of SAR443820 for the Treatment of Amyotrophic Lateral Sclerosis
Shots:
- Sanofi initiate the patient dosing in the P-II (HIMALAYA) study to evaluate the efficacy, safety, PK & PD of SAR443820 (CNS-penetrant RIPK1 inhibitor) in ~260 patients with ALS. The study has built upon the results from the P-I study
- Under the collaboration with Sanofi, Denali to receive a $40M milestone for the P-II (HIMALAYA) study of SAR443820 & is eligible to receive additional development & regulatory milestones along with royalties. Denali will equally share profits & losses with Sanofi for CNS-penetrant products
- SAR443122 has received FTD from the US FDA for ALS & is being studied in the P-II trial for CLE. Sanofi also plans to initiate a P-II trial for UC
Ref: Globenewswire | Image: Denali
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
